UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in Insmed Incorporated (NASDAQ:INSM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Insmed Incorporated (NASDAQ:INSM) by 65.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 422,936 shares of the biopharmaceutical company’s stock after selling 814,319 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.24% of Insmed worth $30,874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of INSM. Ally Bridge Group NY LLC increased its holdings in shares of Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after buying an additional 21,833 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in Insmed during the third quarter valued at about $35,322,000. &PARTNERS bought a new stake in Insmed during the second quarter worth about $300,000. Jennison Associates LLC boosted its holdings in shares of Insmed by 3.4% in the 3rd quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company’s stock worth $56,155,000 after purchasing an additional 24,973 shares in the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Insmed by 58.6% during the 3rd quarter. WCM Investment Management LLC now owns 148,330 shares of the biopharmaceutical company’s stock valued at $10,751,000 after purchasing an additional 54,806 shares during the last quarter.

Insider Transactions at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This represents a 11.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The trade was a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,882 shares of company stock valued at $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Insmed Stock Up 4.0 %

Shares of NASDAQ INSM opened at $75.36 on Thursday. The firm has a fifty day simple moving average of $72.26 and a two-hundred day simple moving average of $69.06. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $13.48 billion, a PE ratio of -13.58 and a beta of 1.10.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. Insmed’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.10) earnings per share. Equities analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. StockNews.com lowered shares of Insmed from a “hold” rating to a “sell” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, November 22nd. TD Cowen upped their price target on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.67.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.